Literature DB >> 36204163

Steroid Management in a Patient with Myasthenia Gravis Undergoing COVID-19 Vaccination.

Angelo Alito1, Carmelo Rodolico2, Michelangelo Palco3, Simona Portaro1.   

Abstract

Entities:  

Year:  2022        PMID： 36204163      PMCID： PMC9507145     

Source DB:  PubMed          Journal:  Innov Clin Neurosci        ISSN： 2158-8333


× No keyword cloud information.
  4 in total

1.  Glucocorticoids administered in vivo inhibit human suppressor T lymphocyte function and diminish B lymphocyte responsiveness in in vitro immunoglobulin synthesis.

Authors:  A Saxon; R H Stevens; S J Ramer; P J Clements; D T Yu
Journal:  J Clin Invest       Date:  1978-04       Impact factor: 14.808

2.  The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020.

Authors:  Nancy McClung; Mary Chamberland; Kathy Kinlaw; Dayna Bowen Matthew; Megan Wallace; Beth P Bell; Grace M Lee; H Keipp Talbot; José R Romero; Sara E Oliver; Kathleen Dooling
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2020-11-27       Impact factor: 17.586

Review 3.  Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations.

Authors:  Laura Dresser; Richard Wlodarski; Kourosh Rezania; Betty Soliven
Journal:  J Clin Med       Date:  2021-05-21       Impact factor: 4.241

4.  Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.

Authors:  Saiju Jacob; Srikanth Muppidi; Amanda Guidon; Jeffrey Guptill; Michael Hehir; James F Howard; Isabel Illa; Renato Mantegazza; Hiroyuki Murai; Kimiaki Utsugisawa; John Vissing; Heinz Wiendl; Richard J Nowak
Journal:  J Neurol Sci       Date:  2020-03-25       Impact factor: 3.181
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.